Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383280 | 0.99 | SPHK1 (0.51) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL2383829 | 0.99 | SPHK1 (0.51) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL2384580 | 0.96 | SPHK1 (0.47) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL2384002 | 0.91 | CYP2C9 (0.48) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL7913866 | 0.89 | SPHK1 (0.59) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL7913864 | 0.89 | SPHK1 (0.59) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL2383839 | 0.88 | SPHK1 (0.40) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL10479901 | 0.88 | SPHK1 (0.57) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL10902554 | 0.88 | SPHK1 (0.57) | SPHK1SPHK2CYP2C9MEN1KMT2A | |
| SCHEMBL10901561 | 0.88 | SPHK1 (0.57) | SPHK1SPHK2CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8512598-B2 | Liquid crystal compounds and method for preparing the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2013-08-20 | — | — | US | disclosed |
| US-20110237849-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | Dongjin Semichem Co., Ltd., (KR) | 2011-09-29 | — | — | US | disclosed |
| WO-2010071335-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237849-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | HCK, NLK, VRK1 | SPHK1 789/4885SPHK2 914/4885CYP2C9 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.